Cappella taps Shea as CEO

Ireland's Cappella Medical Devices has named Paul Shea, a 30-year veteran of the medical device industry, as its new CEO. Shea recently served as senior VP of Sales at Sentinelle Medical and previously was VP of Sales at Traxral. He also has held positions at Angiodynamics and Boston Scientific.

According to its website, Cappella is focusing on developing solutions for the treatment of complex coronary artery disease. It was founded in 2004 and received the CE Mark for its first product, the Sideguard coronary sidebranch stent & delivery system, in April 2009. The Sideguard delivery system features a proprietary split-sheath, balloon-released technology that ensures precise placement on the ostial borderline. The hiring announcement comes as the company is trying to maximize the ongoing growth of the Sideguard technology throughout Europe and South America, according to a statement.

Cappella also announced that it has promoted Art Rosenthal, who recently served as the company's CEO, to executive vice chairman and will be responsible for strategic partnering, clinical development and networking initiatives.

- check out the Cappella release

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.